Preparation and Foliar Application of Oligochitosan - Nanosilica on the Enhancement of Soybean Seed Yield

Oligochitosan with weight average molecu-lar weight (Mw) of 5000 g/mol was prepared by gamma Co-60 radiation degradation of 4% chitosan solution containing 0.5% H2O2 at 21 kGy. Nanosilica with size of 10 – 30 nm was synthesized by calcination of acid treated rice husk at 700o C for 2 h. The mixture of 2% oligo-chitosan-2% nanosilica was prepared by dispersion of nanosilica in oligochitosan solution. Oligochitosan, nanosilica and their mixture were characterized by gel permeation chromatography (GPC), transmission electr-on microscopy (TEM), X-ray diffraction (XRD), energy dispersive x-ray spectroscopy (EDX), Ultraviolet-visible spectroscopy (UV-Vis), and Furrier transform infrared spectroscopy (FT-IR). Effect of foliar application of oli-gochitosan and oligochitosan-nanosilica on soybean seed yield was conducted in experimental field. Results indi-cated that soybean seed yield increased 10.5 and 17.0% for oligochitosan and oligochitosan-nanosilica, respect-tively for the control. Radiation degraded oligo-chitosan and its mixture with nanosilica can be potentially used for cultivation of soybean with enhanced seed yield

Chemical composition, antimicrobial and larvicidal activities of essential oils of two Syzygium species from Vietnam

Abstract The present study is the first to investigate the chemical composition, antimicrobial and larvicidal activities of the essential oils from the leaves of Syzygium attopeuense (Gagnep.) Merr. & L.M.Perry and Syzygium tonkinense (Gagnep.) Merr. & L.M.Perry collected in Vietnam. The essential oils were extracted by hydrodistillation and analyzed by GC and GC–MS. The study indicated the presence of a high percentage of sesquiterpenes in both investigated essential oils. The major components of S. attopeuense essential oil were bicyclogermacrene (24.26%), (E)-caryophyllene (11.72%), and (E)-β-ocimene (6.75%), whereas S. tonkinense essential oil was dominated by (E)-caryophyllene (80.80%). The antimicrobial activity of essential oils was evaluated by broth microdilution assay to determine the minimum inhibitory concentration (MIC) and median inhibitory concentration (IC50). Both essential oils exhibited remarkable inhibitory activity against all tested Gram-positive bacteria and yeast than Gram-negative bacteria. Among them, essential oils of S. attopeuense and S. tonkinense possessed the strongest activity against Enterococcus faecalis (MIC = 4.00 μg/mL; IC50 = 1.69 μg/mL) and Candida albicans (MIC = 16.00 μg/mL; IC50 = 8.67 μg/mL), respectively. Furthermore, the larvicidal activity of essential oils was tested using fourth-instar larvae of Aedes aegypti. Results from the larvicidal test revealed that both essential oils had an excellent inhibitory effect against A. aegypti larvae with LC50 values from 25.55 to 30.18 μg/mL and LC90 values from 33.00 to 39.01 μg/mL. Our findings demonstrate that the essential oil extracted from S. attopeuense and S. tonkinense are potential sources of natural antimicrobials and can act as inexpensive mosquito larvicidal agents

Suboptimal Exposure to Anti-TB Drugs in a TBM/HIV+ Population is not Related to Anti-retroviral Therapy.

A placebo-controlled trial that compares the outcomes of immediate versus deferred initiation of antiretroviral therapy in HIV+ve Tuberculous Meningitis (TBM) patients was conducted in Vietnam in 2011. Here, the pharmacokinetics of Rifampicin, Isoniazid, Pyrazinamide and Ethambutol were investigated in the presence and absence of anti-HIV treatment in 85 patients. Pharmacokinetic analyses show that HIV therapy has no significant impact upon the pharmacokinetics of TB drugs in this cohort. The same population, however, displayed generally low CSF and systemic exposures to rifampicin compared to previously reported HIV –ve cohorts. Elevated CSF concentrations of pyrazinamide on the other hand were strongly and independently correlated with increased mortality and neurological toxicity. The findings suggest that the current standard dosing regimens may put the patient at risk of treatment failure from suboptimal rifampicin exposure, and potentially increasing the risk of adverse CNS events which are independently correlated with pyrazinamide CSF exposure

Intensified Antituberculosis Therapy in Adults with Tuberculous Meningitis

BACKGROUND Tuberculous meningitis is often lethal. Early antituberculosis treatment and adjunctive treatment with glucocorticoids improve survival, but nearly one third of patients with the condition still die. We hypothesized that intensified antituberculosis treatment would enhance the killing of intracerebral Mycobacterium tuberculosis organisms and decrease the rate of death among patients. METHODS We performed a randomized, double-blind, placebo-controlled trial involving human immunodeficiency virus (HIV)-infected adults and HIV-uninfected adults with a clinical diagnosis of tuberculous meningitis who were admitted to one of two Vietnamese hospitals. We compared a standard, 9-month antituberculosis regimen (which included 10 mg of rifampin per kilogram of body weight per day) with an intensified regimen that included higher-dose rifampin (15 mg per kilogram per day) and levofloxacin (20 mg per kilogram per day) for the first 8 weeks of treatment. The primary outcome was death by 9 months after randomization. RESULTS A total of 817 patients (349 of whom were HIV-infected) were enrolled; 409 were randomly assigned to receive the standard regimen, and 408 were assigned to receive intensified treatment. During the 9 months of follow-up, 113 patients in the intensified-treatment group and 114 patients in the standard-treatment group died (hazard ratio, 0.94; 95% confidence interval, 0.73 to 1.22; P=0.66). There was no evidence of a significant differential effect of intensified treatment in the overall population or in any of the subgroups, with the possible exception of patients infected with isoniazid-resistant M. tuberculosis. There were also no significant differences in secondary outcomes between the treatment groups. The overall number of adverse events leading to treatment interruption did not differ significantly between the treatment groups (64 events in the standard-treatment group and 95 events in the intensified-treatment group, P=0.08). CONCLUSIONS Intensified antituberculosis treatment was not associated with a higher rate of survival among patients with tuberculous meningitis than standard treatment. (Funded by the Wellcome Trust and the Li Ka Shing Foundation; Current Controlled Trials number, ISRCTN61649292.)

Functional outcome and muscle wasting in adults with tetanus.

BACKGROUND: In many countries, in-hospital survival from tetanus is increasing, but long-term outcome is unknown. In high-income settings, critical illness is associated with muscle wasting and poor functional outcome, but there are few data from resource-limited settings. In this study we aimed to assess muscle wasting and long-term functional outcome in adults with tetanus. METHODS: In a prospective observational study involving 80 adults with tetanus, sequential rectus femoris ultrasound measurements were made at admission, 7 days, 14 days and hospital discharge. Functional outcome was assessed at hospital discharge using the Timed Up and Go test, Clinical Frailty Score, Barthel Index and RAND 36-item Short Form Health Survey (SF-36) and 3 and 6 months after discharge using the SF-36 and Barthel Index. RESULTS: Significant muscle wasting occurred between hospital admission and discharge (p70 y of age, functional recovery at 6 months was reduced compared with younger patients. Hospital-acquired infection and age were risk factors for muscle wasting. CONCLUSIONS: Significant muscle wasting during hospitalization occurred in patients with tetanus, the extent of which correlates with functional outcome

Combination Antifungal Therapy for Cryptococcal Meningitis

Background Combination antifungal therapy (amphotericin B deoxycholate and flucytosine) is the recommended treatment for cryptococcal meningitis but has not been shown to reduce mortality, as compared with amphotericin B alone. We performed a randomized, controlled trial to determine whether combining flucytosine or high-dose fluconazole with high-dose amphotericin B improved survival at 14 and 70 days. Methods We conducted a randomized, three-group, open-label trial of induction therapy for cryptococcal meningitis in patients with human immunodeficiency virus infection. All patients received amphotericin B at a dose of 1 mg per kilogram of body weight per day; patients in group 1 were treated for 4 weeks, and those in groups 2 and 3 for 2 weeks. Patients in group 2 concurrently received flucytosine at a dose of 100 mg per kilogram per day for 2 weeks, and those in group 3 concurrently received fluconazole at a dose of 400 mg twice daily for 2 weeks. Results A total of 299 patients were enrolled. Fewer deaths occurred by days 14 and 70 among patients receiving amphotericin B and flucytosine than among those receiving amphotericin B alone (15 vs. 25 deaths by day 14; hazard ratio, 0.57; 95% confidence interval [CI], 0.30 to 1.08; unadjusted P=0.08; and 30 vs. 44 deaths by day 70; hazard ratio, 0.61; 95% CI, 0.39 to 0.97; unadjusted P=0.04). Combination therapy with fluconazole had no significant effect on survival, as compared with monotherapy (hazard ratio for death by 14 days, 0.78; 95% CI, 0.44 to 1.41; P=0.42; hazard ratio for death by 70 days, 0.71; 95% CI, 0.45 to 1.11; P=0.13). Amphotericin B plus flucytosine was associated with significantly increased rates of yeast clearance from cerebrospinal fluid (−0.42 log10 colony-forming units [CFU] per milliliter per day vs. −0.31 and −0.32 log10 CFU per milliliter per day in groups 1 and 3, respectively; P<0.001 for both comparisons). Rates of adverse events were similar in all groups, although neutropenia was more frequent in patients receiving a combination therapy. Conclusions Amphotericin B plus flucytosine, as compared with amphotericin B alone, is associated with improved survival among patients with cryptococcal meningitis. A survival benefit of amphotericin B plus fluconazole was not found

Security–Reliability Tradeoff Analysis for SWIPT- and AF-Based IoT Networks With Friendly Jammers

Radio-frequency (RF) energy harvesting (EH) in wireless relaying networks has attracted considerable recent interest, especially for supplying energy to relay nodes in the Internet of Things (IoT) systems to assist the information exchange between a source and a destination. Moreover, limited hardware, computational resources, and energy availability of IoT devices have raised various security challenges. To this end, physical-layer security (PLS) has been proposed as an effective alternative to cryptographic methods for providing information security. In this study, we propose a PLS approach for simultaneous wireless information and power transfer (SWIPT)-based half-duplex (HD) amplify-and-forward (AF) relaying systems in the presence of an eavesdropper. Furthermore, we take into account both static power splitting relaying (SPSR) and dynamic power splitting relaying (DPSR) to thoroughly investigate the benefits of each one. To further enhance secure communication, we consider multiple friendly jammers to help prevent wiretapping attacks from the eavesdropper. More specifically, we provide a reliability and security analysis by deriving closed-form expressions of outage probability (OP) and intercept probability (IP), respectively, for both the SPSR and DPSR schemes. Then, simulations are also performed to validate our analysis and the effectiveness of the proposed schemes. Specifically, numerical results illustrate the nontrivial tradeoff between reliability and security of the proposed system. In addition, we conclude from the simulation results that the proposed DPSR scheme outperforms the SPSR-based scheme in terms of OP and IP under the influences of different parameters on system performance

Invasive Non-typhoidal Salmonella Infections in Asia: Clinical Observations, Disease Outcome and Dominant Serovars from an Infectious Disease Hospital in Vietnam.

Invasive non-typhoidal Salmonella (iNTS) infections are now a well-described cause of morbidity and mortality in children and HIV-infected adults in sub-Saharan Africa. In contrast, the epidemiology and clinical manifestations of iNTS disease in Asia are not well documented. We retrospectively identified >100 cases of iNTS infections in an infectious disease hospital in Southern Vietnam between 2008 and 2013. Clinical records were accessed to evaluate demographic and clinical factors associated with iNTS infection and to identify risk factors associated with death. Multi-locus sequence typing and antimicrobial susceptibility testing was performed on all organisms. Of 102 iNTS patients, 71% were HIV-infected, >90% were adults, 71% were male and 33% reported intravenous drug use. Twenty-six/92 (28%) patients with a known outcome died; HIV infection was significantly associated with death (p = 0.039). S. Enteritidis (Sequence Types (ST)11) (48%, 43/89) and S. Typhimurium (ST19, 34 and 1544) (26%, 23/89) were the most commonly identified serovars; S. Typhimurium was significantly more common in HIV-infected individuals (p = 0.003). Isolates from HIV-infected patients were more likely to exhibit reduced susceptibility against trimethoprim-sulfamethoxazole than HIV-negative patients (p = 0.037). We conclude that iNTS disease is a severe infection in Vietnam with a high mortality rate. As in sub-Saharan Africa, HIV infection was a risk factor for death, with the majority of the burden in this population found in HIV-infected adult men

An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

For a decade, The Cancer Genome Atlas (TCGA) program collected clinicopathologic annotation data along with multi-platform molecular profiles of more than 11,000 human tumors across 33 different cancer types. TCGA clinical data contain key features representing the democratized nature of the data collection process. To ensure proper use of this large clinical dataset associated with genomic features, we developed a standardized dataset named the TCGA Pan-Cancer Clinical Data Resource (TCGA-CDR), which includes four major clinical outcome endpoints. In addition to detailing major challenges and statistical limitations encountered during the effort of integrating the acquired clinical data, we present a summary that includes endpoint usage recommendations for each cancer type. These TCGA-CDR findings appear to be consistent with cancer genomics studies independent of the TCGA effort and provide opportunities for investigating cancer biology using clinical correlates at an unprecedented scale. Analysis of clinicopathologic annotations for over 11,000 cancer patients in the TCGA program leads to the generation of TCGA Clinical Data Resource, which provides recommendations of clinical outcome endpoint usage for 33 cancer types